Talk:Asparaginase

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Asparaginase.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Health Canada may add anti-cancer drug to junk food

Untitled

Research suggests asparaginase reduces the production of acrylamide, a potentially dangerous compound that is created during the high-temperature frying and baking of starchy foods. --Iiaiiappa (talk) 20:28, 30 December 2009 (UTC)[reply]

Edit to Asparaginase Medical Section

This edit request by an editor with a conflict of interest has now been answered.

I'm aware of WP:COI and thus would like to raise to the community a portion of this article that I think could be improved. Can you please consider updating the "Medical" section in the article to add the below text under the third paragraph (chronological order)?

What I think should be changed:

“On July 24, 2006, the U.S. Food and Drug Administration granted approval to pegaspargase for the first-line treatment of patients with acute lymphoblastic leukemia (ALL) as a component of a multiagent chemotherapy regimen. Pegaspargase was previously approved in February 1994 for the treatment of patients with ALL who were hypersensitive to native forms of L-asparaginase. 1,2

On December 20, 2018, the Food and Drug Administration (FDA) approved calaspargase pegol-mknl, an asparagine specific enzyme, as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age 1 month to 21 years. This new product provides for a longer interval between doses compared to other available pegaspargase products. Calaspargase pegol-mknl has received FDA orphan drug designation.3,4”

Why it should be changed: A later approval of a medication using asparaginase is included in this section, and I believe it is important for the public to be aware of the others.

References supporting the possible change (format using the "cite" button):

^[1] ^[2] ^[3] ^[4]

Micaela at Ruder Finn (talk) 17:35, 18 May 2022 (UTC)[reply]

I reviewed your edit request, and honestly, I do not see any reason why we shouldn't add your text. Your edit request is APPROVED, as long as you stick to the text requestedd of course :). Craffael.09 (talk) 22:02, 24 October 2022 (UTC)[reply]

Done ℰmi1y_⧼T·C⧽ 10:31, 21 November 2022 (UTC)[reply]

References

Endemic and ongoing quality-control issues

Hi! We should probably include a controversies-style section detailing the maelstrom of issues with asparaginase that have cropped up over the last few years-- particularly as it's been causing harm to patients, failing to work properly, etc.

It's apparently notable enough to receive a shoutout in Nature's daily briefing (https://www.nature.com/articles/d41586-023-02200-9) which is about as prestigious as journal reporting gets.

Here's a detailed report: https://www.thebureauinvestigates.com/stories/2023-01-25/the-drug-was-meant-to-save-childrens-lives-instead-theyre-dying Atomic putty? Rien! 14:58, 5 July 2023 (UTC)[reply]

[1] 1. https://pubmed.ncbi.nlm.nih.gov/17766659/

[2] 2. https://www.cancernetwork.com/view/fda-approves-oncaspar-first-line-all

[3] 3. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-longer-acting-calaspargase-pegol-mknl-all

[4] 4. https://www.medscape.com/viewarticle/906923

[1]

[2]

[3]

[4]